Fresh from completing its merger with a special purpose acquisition corporation (SPAC), Oculis S.A. can once again focus on the clinical progress of its eye disease pipeline.
NASDAQ Listing Done, Oculis Eyes Phase III Readouts
Decent Cash Position After SPAC Merger
Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.
More from Sensory
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.